This page shows the latest heart attack patients news and features for those working in and with pharma, biotech and healthcare.
or cardiovascular death in adult following an acute myocardial infarction or heart attack. ... secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack.
heart attack and/or death when given to patients who had previously suffered a stroke or transient transient ischaemic attack. ... The drug is already approved for the treatment of acute coronary syndrome (ACS) and for the secondary prevention of
Novartis also plans to conduct ORION-4, the ongoing study for patients who have already had a heart attack or stroke, with this study making the UK the global trial centre. ... In January, Novartis announced that it has teamed up with the NHS which will
When used on its own by patients who had already suffered a stroke or transient ischaemic attack (TIA), it demonstrated a trend towards fewer subsequent events of stroke, heart attack ... The drug is already approved for the treatment of acute coronary
The EU filing comes as Vascepa (icosapent ethyl) is also under review by the FDA for a new label claim that the drug can reduce the incidence of heart attack and ... with Vascepa “major adverse cardiovascular events such as stroke, heart attack and
The benefits of well-managed and well-targeted joint working projects to patients and the NHS – and pharma - are widely accepted on both sides, but these remain relatively few and far ... Examples of successful joint initiatives include one between
More from news
Approximately 1 fully matching, plus 57 partially matching documents found.
Insights reach R&D that ordinarily take years; beta-blockers, for example, found expanded use to control hypertension only after retrospective analysis of four decades of use in heart attack patients.”. ... We create thousands of patient leaflets
Published: 21 Nov 2011. AZ’s patient support programme provided holistic support to newly diagnosed heart attack patients. ... Improve discharge information. Maximise adherence to medication. Address psychological health. AstraZeneca also launched a
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
In this case, of the male patients with ACS, 27% experienced angina and 73% experienced a heart attack. ... This quickly demonstrates that the majority of male patients who experience a heart attack will be found within the non ST-elevated heart attack
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...